Logo image of ETNB

89BIO INC (ETNB) Stock Fundamental Analysis

NASDAQ:ETNB - Nasdaq - US2825591033 - Common Stock - Currency: USD

6.06  +0.17 (+2.89%)

After market: 6.12 +0.06 (+0.99%)

Fundamental Rating

2

Taking everything into account, ETNB scores 2 out of 10 in our fundamental rating. ETNB was compared to 568 industry peers in the Biotechnology industry. ETNB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ETNB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ETNB has reported negative net income.
In the past year ETNB has reported a negative cash flow from operations.
ETNB had negative earnings in each of the past 5 years.
In the past 5 years ETNB always reported negative operating cash flow.
ETNB Yearly Net Income VS EBIT VS OCF VS FCFETNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -76.68%, ETNB is doing worse than 67.78% of the companies in the same industry.
Looking at the Return On Equity, with a value of -91.59%, ETNB is in line with its industry, outperforming 48.42% of the companies in the same industry.
Industry RankSector Rank
ROA -76.68%
ROE -91.59%
ROIC N/A
ROA(3y)-50.79%
ROA(5y)-46.26%
ROE(3y)-61.77%
ROE(5y)-56.24%
ROIC(3y)N/A
ROIC(5y)N/A
ETNB Yearly ROA, ROE, ROICETNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ETNB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ETNB Yearly Profit, Operating, Gross MarginsETNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ETNB has more shares outstanding
ETNB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ETNB is higher compared to a year ago.
ETNB Yearly Shares OutstandingETNB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ETNB Yearly Total Debt VS Total AssetsETNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 2.85 indicates that ETNB is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.85, ETNB is doing good in the industry, outperforming 77.29% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that ETNB is not too dependend on debt financing.
ETNB's Debt to Equity ratio of 0.09 is on the low side compared to the rest of the industry. ETNB is outperformed by 64.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 2.85
ROIC/WACCN/A
WACCN/A
ETNB Yearly LT Debt VS Equity VS FCFETNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 13.19 indicates that ETNB has no problem at all paying its short term obligations.
ETNB has a better Current ratio (13.19) than 86.97% of its industry peers.
A Quick Ratio of 13.19 indicates that ETNB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 13.19, ETNB belongs to the top of the industry, outperforming 86.97% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.19
Quick Ratio 13.19
ETNB Yearly Current Assets VS Current LiabilitesETNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

ETNB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -70.65%.
EPS 1Y (TTM)-70.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ETNB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.91% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y41.92%
EPS Next 2Y18.36%
EPS Next 3Y12.37%
EPS Next 5Y13.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ETNB Yearly Revenue VS EstimatesETNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
ETNB Yearly EPS VS EstimatesETNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ETNB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ETNB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ETNB Price Earnings VS Forward Price EarningsETNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ETNB Per share dataETNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ETNB's earnings are expected to grow with 12.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.36%
EPS Next 3Y12.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ETNB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

89BIO INC

NASDAQ:ETNB (4/17/2025, 8:15:49 PM)

After market: 6.12 +0.06 (+0.99%)

6.06

+0.17 (+2.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners100.95%
Inst Owner Change0%
Ins Owners1.33%
Ins Owner Change18.9%
Market Cap884.64M
Analysts84.71
Price Target28.1 (363.7%)
Short Float %6.76%
Short Ratio4.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-71.04%
Min EPS beat(2)-112.45%
Max EPS beat(2)-29.63%
EPS beat(4)1
Avg EPS beat(4)-34.86%
Min EPS beat(4)-112.45%
Max EPS beat(4)17.4%
EPS beat(8)3
Avg EPS beat(8)-18.39%
EPS beat(12)6
Avg EPS beat(12)-7.99%
EPS beat(16)7
Avg EPS beat(16)-9.33%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.15%
PT rev (3m)-9.05%
EPS NQ rev (1m)-2.92%
EPS NQ rev (3m)27.91%
EPS NY rev (1m)24.66%
EPS NY rev (3m)34.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.21
P/tB 2.21
EV/EBITDA N/A
EPS(TTM)-3.43
EYN/A
EPS(NY)-1.99
Fwd EYN/A
FCF(TTM)-2.52
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0
BVpS2.75
TBVpS2.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.68%
ROE -91.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.79%
ROA(5y)-46.26%
ROE(3y)-61.77%
ROE(5y)-56.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.19
Quick Ratio 13.19
Altman-Z 2.85
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)20.59%
Cap/Depr(5y)70.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104%
EPS Next Y41.92%
EPS Next 2Y18.36%
EPS Next 3Y12.37%
EPS Next 5Y13.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-154.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.71%
EBIT Next 3Y-4.05%
EBIT Next 5YN/A
FCF growth 1Y-184.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-184.72%
OCF growth 3YN/A
OCF growth 5YN/A